Rongchang Biopharmaceutical: RC148 Receives Breakthrough Therapy Designation from CDE

Rongchang Bio announced that the company's original research new bispecific antibody RC148 has been officially included in the breakthrough therapeutic drug category by the Drug Evaluation Center of China National Medical Products Administration. The indication is for the use of RC148 in combination with docetaxel to treat locally advanced or metastatic non-small cell lung cancer with driver gene-negative tumors that have failed treatment with PD-1/PD-L1 inhibitors and platinum-based chemotherapy.